Aclarion (NASDAQ: ACON) Maintains Hold Rating from Maxim Group

Aclarion, Inc. (NASDAQ: ACON) has recently had its stock rating reaffirmed as a "hold" by analysts at Maxim Group. This rating was highlighted in a research report that was released on Friday, as reported by Benzinga.

Additionally, Ascendiant Capital Markets provided an update on Aclarion's stock valuation by lowering its price target from $1.50 to $1.30. They have expressed a "buy" rating for the company in their research note published on November 27th.

Aclarion's Stock Performance

On Friday, Aclarion shares opened at $0.11. The company has seen significant fluctuations over the past year, with a low of $0.10 and a high of $7.40. Currently, the stock is performing below its moving averages, with a 50-day simple moving average at $0.18 and a 200-day simple moving average at $0.23.

About Aclarion

Aclarion specializes in healthcare technology, focusing on Magnetic Resonance Spectroscopy (MRS) in the United States. The company has developed a suite of software applications known as the NOCISCAN Post-Processor, which includes tools like NOCICALC and NOCIGRAM. NOCICALC is designed to process raw MRS exam data into final spectra and perform various biomarker analyses related to degenerative pain, while NOCIGRAM serves as a clinical decision support software.

Aclarion, stock, Maxim